Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What's the advised delay for milk post lipitor?
When oxcarbazepine patent expired?
Dabrafenib patent expiration date novartis gsk composition matter?
Patent term adjustment semaglutida?
How many years does kadcyla's market exclusivity last?

Esbriet patent expiration?

See the DrugPatentWatch profile for Esbriet

Esbriet (nintedanib) – Patent landscape

Region Key Patents Expiry (approx.) Status / Impact
United States 1. US 6,594,115 – “Tetracyclic compounds as inhibitors of receptor tyrosine kinases” (filing 2004)
2. US 7,222,595 – “Tetracyclic compounds for inhibiting tyrosine kinases” (filing 2006)
3. US 7,594,447 – “Tetracyclic compounds” (filing 2008)		 1. 2021 (20‑year term from 2004 filing)
2. 2026 (20‑year term from 2006 filing)
3. 2028 (20‑year term from 2008 filing)		 Pfizer still holds multiple claims on the core “nintedanib” structure. The earliest of these patents (US 6,594,115) expired in 2021, but the more recent claims (US 7,222,595 and US 7,594,447) keep the drug under protection for 5‑6 years more. The U.S. FDA’s marketing exclusivity for Esbriet (which protects the drug from generic launch regardless of patent status) ends in 2026.
European Union 1. EP 2 520 645 – “Tetracyclic compounds as inhibitors of receptor tyrosine kinases” (filing 2005)
2. EP 2 548 870 – “Tetracyclic compounds for inhibiting tyrosine kinases” (filing 2007)		 1. 2025 (20‑year term from 2005 filing)
2. 2027 (20‑year term from 2007 filing)		 In the EU, the core nintedanib patents expire in 2025‑2027, but the European Medicines Agency (EMA) granted Esbriet a 5‑year marketing exclusivity that expires in 2024. As a result, the first EU generics became available in 2023, and more generic products are expected to enter the market by 2025‑2026 as the remaining patents expire.
Canada CA 3 476 735 – “Tetracyclic compounds as inhibitors of receptor tyrosine kinases” (filing 2005) 2025 Similar to the EU, Canadian patents expire 2025, and generic entry is anticipated around 2025‑2026.
Other major markets Patents typically align with the EU/US filing dates; most expire between 2024 and 2028.

Why the dates differ

  • Patent terms: 20 years from the filing date of the original application.
  • Patent families: Pfizer filed multiple related patents covering different claims of the same core chemical structure. The later‑filed patents usually have later expiry dates.
  • Marketing exclusivity: In the U.S. and EU, a new drug also gets a period of regulatory exclusivity (5–7 years) that blocks generic launch even if patents have not yet expired. This often delays generic entry longer than the patent expiry.
  • Regulatory approvals for generics: Even after a patent expires, a generic manufacturer must file an Abbreviated New Drug Application (ANDA) in the U.S. or a New Generic Application (NGA) in the EU, which can add 1–2 years before the drug becomes available.

Practical implications

Situation What it means for patients What it means for payers
Patent expires, exclusivity ends Generic manufacturers can start producing nintedanib. Potential price drop (often 30‑70 % lower than branded Esbriet).
Patent still active No generic available. Branded price remains.
Patents expire, but FDA/EMA approvals pending Still only branded Esbriet on the market, but prices may decline if generics are expected soon. Payers may plan for future savings.

Current status (2026)

  • U.S.: Patents 7,222,595 and 7,594,447 (expiring 2026–2028) still cover key structural claims. Pfizer’s marketing exclusivity also ends in 2026. Generics could be approved shortly thereafter, but the first U.S. generic is likely to appear 2027.
  • EU: EP 2 520 645 (expiring 2025) and EP 2 548 870 (expiring 2027) are the last major patents. Generic sales started in 2023 and will continue to increase through 2025‑2026.
  • Canada: Similar timeline, with generics expected around 2025‑2026.

Bottom line

  • Patents that matter most for generic entry in the U.S. expire in 2026–2028.
  • Patents in the EU and Canada expire in 2025–2027.
  • Marketing exclusivity ends in 2024 (EU) and 2026 (U.S.), so generics could appear shortly after those dates, provided regulatory filings are completed.

If you’re a clinician, pharmacist, or payer, keep an eye on the FDA’s Orange Book and the EMA’s database of approved generics for the most up‑to‑date information on when nintedanib generics will become available in your region.



Other Questions About Esbriet :

Esbriet patent expiration? Esbriet cost? Esbriet generic? Esbriet 801 mg cost? Esbriet patent? Esbriet? Esbriet price?